Advertisement Sagent launches ciprofloxacin injection - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

Sagent launches ciprofloxacin injection

Sagent Pharmaceuticals has launched ciprofloxacin injection, USP, 5% dextrose premix bag, a synthetic broad spectrum antimicrobial agent for intravenous administration used to treat bacterial infections.

Sagent’s ciprofloxacin injection will be available immediately in 200mg and 400mg premix bags. Ciprofloxacin injection, USP, is a synthetic broad spectrum antimicrobial agent and is the generic equivalent of Bayer Pharmaceuticals’s Cipro I.V.

Jeffrey Yordon, CEO and founder of Sagent, said: “The launch of our ciprofloxacin further demonstrates Sagent’s capabilities and expertise in injectable pharmaceutical products and our seasoned management team’s commitment to the needs of patients and customers.”